Showing 2121-2130 of 3039 results for "".
- Aurion Biotech Announces IOTA Cell Therapy Trialhttps://modernod.com/news/aurion-biotech-announces-iota-cell-therapy-trial/2479415/Aurion Biotech announced preliminary findings from its IOTA trial, conducted in November 2020 and in May of this year, at the Clínica Quesada in San Salvador, El Salvador. In the IOTA trial, 50 patients diagnosed with corneal endothelial disease were treated with a transformational cell th
- New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopiahttps://modernod.com/news/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-novel-treatment-for-presbyopia/2479409/Allergan announced new data, including the full results from the phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. Multiple data presentations at the 2021
- Alcon Reinforces Strength of Ophthalmology Portfolio With Surgical Device Scientific Presence at ASCRShttps://modernod.com/news/alcon-reinforces-strength-of-ophthalmology-portfolio-with-surgical-device-scientific-presence-at-ascrs/2479398/Alcon will present a breadth of data during the American Society of Cataract and Refractive Surgery (ASCRS) 2021 annual meeting, taking place July 23-27 in Las Vegas. More than 60 abstracts featuring Alcon ophthalmic products and equipment will be presented. The full abstract book, registration l
- Harrow Health Granted Two Patents for Novel Surgical Dilation Formulationhttps://modernod.com/news/harrow-health-granted-two-patents-for-novel-surgical-dilation-formulation/2479377/Harrow Health announced that the United States Patent and Trademark Office issued two patents, entitled “Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof.” Harrow Health’s wholly owned subsidiary, ImprimisRx, provides surgical dilation (
- Pfizer Plans to Seek FDA Nod for COVID-19 Booster Next Month as Delta Spreadshttps://modernod.com/news/pfizer-plans-to-seek-fda-nod-for-covid-19-booster-next-month-as-delta-spreads/2479354/Pfizer’s chief scientific officer Mikael Dolsten indicated Thursday that the company plans to seek an FDA emergency-use authorization next month for a third dose of its COVID-19 vaccine BNT162b2, according to a FirstWord report. The mRNA-based vaccine, partnered with BioNTech, is cur
- Oasis TEARS PF PLUS Preservative-Free Lubricant Eye Drops Now Delivered in a Bottlehttps://modernod.com/news/oasis-tears-pf-plus-preservative-free-lubricant-eye-drops-now-delivered-in-a-bottle/2479338/Oasis Medical is launching Oasis TEARS PF PLUS preservative-free lubricant eye drops delivered in a 10mL bottle for multiuse. Lubricant eye drops, which are packaged in traditional multi-use bottles, contain preservatives to prevent microbial growth. Preservative-free lubricant eye drops a
- Kala Pharmaceuticals Announces Eysuvis Now Covered by OptumRxhttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-optumrx/2479263/Kala Pharmaceuticals announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021. “We are pleased to announce
- Rayner Receives FDA Approval for RayOne Spheric Monofocal IOLhttps://modernod.com/news/rayner-receives-fda-approval-for-rayone-spheric-monofocal-iol/2479221/Rayner has received FDA approval for the RayOne Spheric fully-preloaded monofocal IOL. The approval marks Rayner’s third FDA approval in under 3 years within its RayOne preloaded IOL portfolio. RayOne Spheric joins RayOne Aspheric (FDA approved December 2018) and RayOne EMV, a new non-diffractive
- New Partnership Expands Alcon’s In-Office Dry Eye and Ocular Health Portfoliohttps://modernod.com/news/new-partnership-expands-alcons-in-office-dry-eye-and-ocular-health-portfolio/2479180/Alcon has gained exclusive rights to sell the technology and accompanying products of BlephEx, a provider of bacterial biofilm theory, in the United States effective May 1, 2021. Terms of the deal were not disclosed. The BlephEx eyelid cleaning device and LashCam iR WIFI
- Pfizer, BioNTech Seek EU Nod to Allow COVID-19 Vaccine Use in Younger Teenshttps://modernod.com/news/pfizer-biontech-seek-eu-nod-to-allow-covid-19-vaccine-use-in-younger-teens/2479158/Pfizer and BioNTech said they have asked the European Medicines Agency (EMA) to extend the conditional marketing authorization for their COVID-19 vaccine Comirnaty to adolescents 12 to 15 years of age. The companies recently made a similar request to the FDA for the vaccine, which is already auth